Study to assess MEDI -578 in patients with Osteoarthritis (OA) of the knee
Study identifier:D2460C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, after Single Ascending Doses in Male and Non-fertile Female Patients with Painful Osteoarthritis of the Knee
Medical condition
Osteoarthritis, Pain
Phase
Phase 1
Healthy volunteers
No
Study drug
MEDI-578, Placebo for MEDI-578
Sex
All
Actual Enrollment
108
Study type
Interventional
Age
40 Years - 80 Years
Date
Study Start Date: 01 Feb 2010
Primary Completion Date: 01 Sept 2010
Study Completion Date: 01 Sept 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
MedImmune
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: MEDI-578 intravenous infusion, once |
| Placebo Comparator: 2 | Drug: Placebo for MEDI-578 Intravenous infusion, once |
Contacts
Investigators
Principal Investigator
Rolf Karlsten
AstraZeneca RD Södertälje
